Anticancer Agent Shikonin Is an Incompetent Inducer of Cancer Drug Resistance

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Wu, Hao ^a   Xie, Jiansheng ^a   Pan, Qiangrong ^a   Wang, Beibei ^a   Hu, Danqing ^a   Hu, Xun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA II TUBULIN; BETA TUBULIN; CISPLATIN; DOXORUBICIN; METHOTREXATE; PACLITAXEL; SHIKONIN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG RESISTANCE; DRUG STRUCTURE; GENE EXPRESSION PROFILING; MOLECULAR INTERACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; MCF-7 CELLS; NAPHTHOQUINONES; NEOPLASMS; PACLITAXEL; TIME FACTORS;

EID: 84871910169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052706     Document Type: Article

References (54)

1. Gottesman MM, (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
2. Gottesman MM, Fojo T, Bates SE, (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
3. Relling MV, Dervieux T, (2001) Pharmacogenetics and cancer therapy. Nat Rev Cancer 1: 99-108.
4. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA, (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204.
5. Cotter TG, (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9: 501-507.
6. Hoskins JM, Carey LA, McLeod HL, (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9: 576-586.
7. Ahn BZ, Baik KU, Kweon GR, Lim K, Hwang BD, (1995) Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem 38: 1044-1047.
8. Bailly C, (2000) Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 7: 39-58.
9. Plyta ZF, Li T, Papageorgiou VP, Mellidis AS, Assimopoulou AN, et al. (1998) Inhibition of topoisomerase I by naphthoquinone derivatives. Bioorg Med Chem Lett 8: 3385-3390.
10. Masuda Y, Nishida A, Hori K, Hirabayashi T, Kajimoto S, et al. (2003) Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 22: 1012-1023.
11. Nakaya K, Miyasaka T, (2003) A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs 14: 683-693.
12. Kim SH, Kang IC, Yoon TJ, Park YM, Kang KS, et al. (2001) Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett 172: 171-175.
13. Masuda Y, Shima G, Aiuchi T, Horie M, Hori K, et al. (2004) Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem 279: 42503-42515.
14. Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK, et al. (2004) Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem 52: 6330-6337.
15. Yoon Y, Kim YO, Lim NY, Jeon WK, Sung HJ, (1999) Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med 65: 532-535.
16. Yang H, Zhou P, Huang H, Chen D, Ma N, et al. (2009) Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459.
17. Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y, Otsuka H, (1977) Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo) 25: 2392-2395.
18. Sankawa U, Otsuka H, Kataoka Y, Iitaka Y, Hoshi A, et al. (1981) Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives. Chem Pharm Bull (Tokyo) 29: 116-122.
19. Hayashi M, (1977) [Pharmacological studies of Shikon and Tooki. (2) Pharmacological effects of the pigment components, Shikonin and acetylshikonin]. Nihon Yakurigaku Zasshi 73: 193-203.
20. Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D, Nicolaou KC, (1999) The Chemistry and Biology of Alkannin, Shikonin, and Related Naphthazarin Natural Products. Angewandte Chemie International Edition 38: 270-301.
21. Guo XP, Zhang XY, Zhang SD, (1991) [Clinical trial on the effects of shikonin mixture on later stage lung cancer]. Zhong Xi Yi Jie He Za Zhi 11: 598-580, 598-599, 580.
22. Li L, Han W, Gu Y, Qiu S, Lu Q, et al. (2007) Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res 67: 4894-4903.
23. Xuan Y, Hu X, (2009) Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett 274: 233-242.
24. Hu X, Han W, Li L, (2007) Targeting the weak point of cancer by induction of necroptosis. Autophagy 3: 490-492.
25. Han W, Li L, Qiu S, Lu Q, Pan Q, et al. (2007) Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6: 1641-1649.
26. Hu X, Xuan Y, (2008) Bypassing cancer drug resistance by activating multiple death pathways-a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett 259: 127-137.
27. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, et al. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1: 112-119.
28. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, et al. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313-321.
29. Degterev A, Yuan J, (2008) Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9: 378-390.
30. Chen J, Xie J, Jiang Z, Wang B, Wang Y, et al. (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene.
31. Altenberg B, Greulich KO, (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020.
32. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, et al. (2009) Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 315: 2765-2774.
33. Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, et al. (2008) Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer 123: 312-321.
34. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
35. Ling CQ, Li B, Zhang C, Zhu DZ, Huang XQ, et al. (2005) Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma. Ann Oncol 16: 109-115.
36. Chen J, Xie J, Jiang Z, Wang B, Wang Y, et al. (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30: 4297-4306.
37. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
38. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
39. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
40. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
41. Floreani M, Napoli E, Palatini P, (2000) Protective action of cardiac DT-diaphorase against menadione toxicity in guinea pig isolated atria. Biochem Pharmacol 60: 601-605.
42. Seve P, Dumontet C, (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9: 168-175.
43. Hu X, Yang H, Pan QR, Zheng S, (1995) Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox? Chemotherapy 41: 296-305.
44. Qiangrong P, Wang T, Lu Q, Hu X, (2005) Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 335: 406-411.
45. Pan Q, Lu Q, Zhang K, Hu X, (2006) Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 58: 99-106.
46. Xu D, Lu Q, Hu X, (2006) Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 243: 274-280.
47. Li L, Pan Q, Sun M, Lu Q, Hu X, (2007) Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1. Life Sci 80: 741-748.
48. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
49. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, et al. (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5: 3352-3356.
50. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH, (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59: 4237-4241.
51. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI, (1995) Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593-1602.
52. Lau DH, Lewis AD, Ehsan MN, Sikic BI, (1991) Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51: 5181-5187.
53. Yeh PY, Chuang SE, Yeh KH, Song YC, Cheng AL, (2003) Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochem Pharmacol 66: 25-33.
54. Han W, Xie J, Li L, Liu Z, Hu X, (2009) Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 14: 674-686.